PIK3CA and adenocarcinoma: In conclusion, this study has showed that, in contrast to adenocarcinomas, in squamous non-small-cell lung cancer, chemotherapy combined with targeted therapies directed at the PI3K or MAPK pathways, or against alterations in CDNK2A gene, was more effective than each treatment tested alone.